Endocrine Testing Market Size, Share, Growth, Report - 2035

The Endocrine Testing Market was valued at
USD 3.4 billion in 2025 and is projected to grow at approximately 8.2% annually
from 2026 to 2035. The market covers assays, instruments, reagents, and
laboratory workflows for hormone and biomarker testing.

Technological advances, healthcare
expansion in APAC, and consumer access to reproductive-health testing support
demand. Automation, broad assay menus, and service coverage help laboratories
manage recurring consumables and high-throughput testing needs.

Based on test type, hCG hormone testing is
projected to reach USD 2,186.36 million by 2035. It supports pregnancy
detection, serial monitoring, emergency medicine, fertility care, and consumer
testing channels.

By technology, Immunoassay is projected to
reach USD 2,823.38 million by 2035. Its position reflects throughput, broad
menus, established clinical workflows, and reagent economics.

Browse complete summary of this research
report @ https://www.gminsights.com/industry-analysis/endocrine-testing-market

North America is projected to reach USD
2,972.48 million by 2035. High diabetes prevalence, reference-laboratory
capacity, automated immunoassay, and menu expansion support its position.

Roche led with over 12% market share in
2025. It combines Elecsys immunoassays and cobas analyzers with clinical mass
spectrometry.

Some of the major players in this market are Abbott, Thermo Fisher Scientific,
Beckman Coulter, Bio-Rad, Siemens Healthineers, SCIEX, DiaSorin, Tosoh
Bioscience, QuidelOrtho, Snibe Diagnostic, Autobio, DRG International,
Monobind, and Merck.